The company builds on Premier's eight-year track record of direct contracting for healthcare supplies and extends existing programmes that are successfully providing uninterrupted access to more than 91 shortage stock keeping units.
This new company, ProvideGx, provides a vehicle for Premier to invest in innovative new business models and partnerships to address drug shortages, including partnering with quality generic drug manufacturers that can supply shortage products, co-funding the development of affordable products that address specific market needs, and securing contracts for active pharmaceutical ingredients to ensure a continuous supply as well as strategic sourcing agreements.
ProvideGx has already partnered with five generic manufacturers to address a targeted pipeline of 60 crucial drugs, and expects to begin marketing additional shortage products next month, pending approval by the US Food and Drug Administration.
According to the University of Utah Drug Information Service, 224 vital medications are in current shortage nationwide, including antimicrobials, cardiovascular drugs, sedation medications, electrolytes, nutritional supplements and chemotherapy drugs.
As a result of these persistent shortages, 96% of health systems report that securing an adequate source of supply is a near constant challenge.
ProvideGx is guided by 31 Premier member health systems and the company's National Pharmacy Committee, representing more than 1,000 hospitals across the nation.
Revenues from the new company are not expected to materially impact Premier FY 2019 results.
Premier Inc. (NASDAQ: PINC) is a healthcare improvement company, uniting an alliance of more than 4,000 US hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy